1. Scrip
  2. >>Business

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

Surrozen Raises Up To $192.5m In Private Placement

 
• By Mandy Jackson

Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.

Finance Watch Public Company
• Source: Alamy

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc.’s $100m IPO on 27 March, outpacing 2023 when 21 firms went public for an average of about five per quarter. Returns are another story, however, with the 10 companies that have gone public so far this year – including Contineum Therapeutics Inc. with a $100m IPO on 4 April – delivering an average 9.7% loss as of 15 April.

Only three of the companies that have gone public in 2024 were trading above their IPO values as of mid-April, showing a decline from 1 March when the first eight drug developers to go public in the US generated an average return of 13%, with half of the companies trading above their IPO prices

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.